Europe Rapid Acting Insulin Market Size, Share, Growth, 2027

Europe Rapid Acting Insulin Market By Product Type (Insulin Lispro, Insulin Aspart and Insulin Glulisine), By Indication (Type 2 Diabetes and Type 1 Diabetes), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers), By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027

Published Date: May-2021 | Number of Pages: 88 | Format: PDF | Report ID: KBV-14825

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Rapid Acting Insulin Market, by Product Type
1.4.2 Europe Rapid Acting Insulin Market, by Indication
1.4.3 Europe Rapid Acting Insulin Market, by Distribution Channel
1.4.4 Europe Rapid Acting Insulin Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)

Chapter 4. Europe Rapid Acting Insulin Market by Product Type
4.1 Europe Insulin Lispro Market by Country
4.2 Europe Insulin Aspart Market by Country
4.3 Europe Insulin Glulisine Market by Country

Chapter 5. Europe Rapid Acting Insulin Market by Indication
5.1 Europe Type 2 Diabetes Market by Country
5.2 Europe Type 1 Diabetes Market by Country

Chapter 6. Europe Rapid Acting Insulin Market by Distribution Channel
6.1 Europe Hospital Pharmacies Market by Country
6.2 Europe Drug Stores & Retail Pharmacies Market by Country
6.3 Europe Online Providers Market by Country

Chapter 7. Europe Rapid Acting Insulin Market by Country
7.1 Germany Rapid Acting Insulin Market
7.1.1 Germany Rapid Acting Insulin Market by Product Type
7.1.2 Germany Rapid Acting Insulin Market by Indication
7.1.3 Germany Rapid Acting Insulin Market by Distribution Channel
7.2 UK Rapid Acting Insulin Market
7.2.1 UK Rapid Acting Insulin Market by Product Type
7.2.2 UK Rapid Acting Insulin Market by Indication
7.2.3 UK Rapid Acting Insulin Market by Distribution Channel
7.3 France Rapid Acting Insulin Market
7.3.1 France Rapid Acting Insulin Market by Product Type
7.3.2 France Rapid Acting Insulin Market by Indication
7.3.3 France Rapid Acting Insulin Market by Distribution Channel
7.4 Russia Rapid Acting Insulin Market
7.4.1 Russia Rapid Acting Insulin Market by Product Type
7.4.2 Russia Rapid Acting Insulin Market by Indication
7.4.3 Russia Rapid Acting Insulin Market by Distribution Channel
7.5 Spain Rapid Acting Insulin Market
7.5.1 Spain Rapid Acting Insulin Market by Product Type
7.5.2 Spain Rapid Acting Insulin Market by Indication
7.5.3 Spain Rapid Acting Insulin Market by Distribution Channel
7.6 Italy Rapid Acting Insulin Market
7.6.1 Italy Rapid Acting Insulin Market by Product Type
7.6.2 Italy Rapid Acting Insulin Market by Indication
7.6.3 Italy Rapid Acting Insulin Market by Distribution Channel
7.7 Rest of Europe Rapid Acting Insulin Market
7.7.1 Rest of Europe Rapid Acting Insulin Market by Product Type
7.7.2 Rest of Europe Rapid Acting Insulin Market by Indication
7.7.3 Rest of Europe Rapid Acting Insulin Market by Distribution Channel

Chapter 8. Company Profiles
8.1 Merck & Co., Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Acquisition and Mergers:
8.2 Sanofi S.A.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Product Launches and Product Expansions:
8.2.5.2 Approvals and Trials:
8.3 Novo Nordisk A/S
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental & Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Product Launches and Product Expansions:
8.3.5.2 Approvals and Trials:
8.3.5.3 Partnerships, Collaborations, and Agreements:
8.4 Eli Lilly and Company
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Product Launches and Product Expansions:
8.4.5.2 Approvals and Trials:
8.4.5.3 Partnerships, Collaborations, and Agreements:
8.5 Adocia SA
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expense
8.5.4 Recent strategies and developments:
8.5.4.1 Approvals and Trials:
8.6 Biocon Limited
8.6.1 Company Overview
8.6.2 Recent strategies and developments:
8.6.2.1 Approvals and Trials:
8.7 Gan & Lee Pharmaceuticals
8.7.1 Company Overview
8.7.2 Financial Analysis
8.8 Geropharm LLC
8.8.1 Company Overview
8.9 Wockhardt Ltd.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.10. MannKind Corporation
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expense
8.10.4 Recent strategies and developments:
8.10.4.1 Acquisition and Mergers:
8.10.4.2 Partnerships, Collaborations, and Agreements:

Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities